ELOXX PHARMACEUTICALS INC
COM · CUSIP 29014R103
0
institutional holders
-1 vs Q4 2022
—reported value*
0 new
0 added
0 reduced
1 sold out
net sold ≈ $27.0k (-14.6k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q1 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 33 |
| Q4 2022 | 1 |
| Q1 2023 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 0 | 32 |
| Q1 2023 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| Clal Insurance Enterprises Holdings Ltd | Sold out | -14.6k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Domicilium Real Estate Fund III LP 13G · passive investor new · filed 2026-05-04 | 18.6% |
| Coastlands Capital LP 13G · institution +5.0 pts · filed 2026-06-17 | 10.0% |
| Aberdeen Group plc 13G · institution new · filed 2026-07-27 | 9.9% |
Holders, Q1 2023
| Manager | Shares | Change |
|---|